Enanta Pharmaceuticals Inc. has presented heterocyclic compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.
Shanghai Allygen Biologics Co. Ltd. has synthesized new antibody-drug conjugates (ADC) comprising antibodies targeting programmed cell death 1 ligand 1 (CD274; PD-L1) covalently linked to SN-38 through a linker and reported to be useful for the treatment of cancer.
Aqualung Therapeutics Corp. has been awarded two 3-year National Institutes of Health (NIH) Fast Track awards to support development of ALT-100 (enamptcumab), a humanized monoclonal antibody therapy for the chronic indications of pulmonary arterial hypertension (PAH) and inflammatory bowel disease (IBD).
Researchers have designed a 3D model of lung cancer that is composed of bronchial epithelial, fibroblasts, epithelial, lung adenocarcinoma and immune cells grown in different layers in a matrigel.
The University of Bari Aldo Moro presented data from an in vivo study assessing the effects of irisin on pancreatic islets of diabetic mice (type 2 diabetes).
Abpro Corp. has entered into a strategic partnership with Celltrion Holdings Co. Ltd. for ABP-102, a bispecific antibody therapy for patients with HER2+ cancer, including breast, gastric and pancreatic cancers.
Researchers from Jagiellonian University presented the discovery of novel multifunctional inhibitors of phosphodiesterases (PDEs) and transient receptor potential ankyrin 1 (TRPA1) antagonists as potential therapeutic candidates for the treatment for chronic airway disorders.
Autosomal dominant hypocalcemia (ADH) type 1 and 2 are disorders that affect calcium homeostasis caused by gain-of-function mutations in CaSR, which encodes the calcium-sensing receptor.
Researchers from Consejo Superior de Investigaciones Cientificas (CSIC) and affiliated organizations presented the discovery of a novel series of compounds acting as Ebola virus (EBOV) entry inhibitors.
RSS
